Literature DB >> 15580553

Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.

Thierry Soussi1, Shunsuke Kato, Pierre P Levy, Chikashi Ishioka.   

Abstract

TP53 alteration is the most frequent genetic alteration found in human cancers. To date, more than 15,000 tumors with TP53 mutations have been published, leading to the description of more than 1,500 different TP53 mutants (http://p53.curie.fr). The frequency of these mutants is highly heterogeneous, with 11 hotspot mutants found more than 100 times, whereas 306 mutants have been reported only once. So far, little is known concerning the biological significance of these rare mutants, as the majority of biological studies have focused on classic hotspot mutants. In order to gain a deeper knowledge about the significance of all of these mutants, we have cross-checked each mutant of the TP53 mutation database for its activity, derived from a library of 2,314 TP53 mutants representing all possible amino acid substitutions caused by a point mutation. The transactivation activity of all of these mutant was analyzed with respect to eight transcription promoters [Kato S, et al., Proc Natl Acad Sci USA (2003)100:8424-8429]. Although the most frequent TP53 mutants sustain a clear loss of transactivation activity, more than 50% of the rare TP53 mutants display significant activity. Analysis in specific types of cancer or in normal skin patches demonstrates a similar distribution of TP53 loss of activity, with the exception of melanoma, in which the majority of TP53 mutants display significant activity. Our data indicate that TP53 mutants represent a highly heterogeneous population with a large diversity in terms of loss of transactivation activity that could account for the heterogeneous tumor phenotypes and the difficulty of clinical studies. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15580553     DOI: 10.1002/humu.20114

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  49 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

3.  High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma.

Authors:  Kiyotaka Saito; Kiyotaka Yokogami; Kazunari Maekawa; Yuichiro Sato; Shinji Yamashita; Fumitaka Matsumoto; Asako Mizuguchi; Hideo Takeshima
Journal:  Hum Cell       Date:  2021-01-17       Impact factor: 4.174

4.  A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.

Authors:  Zhihe Liu; Guanghua Wan; Christopher Heaphy; Marco Bisoffi; Jeffrey K Griffith; Chien-An A Hu
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.396

Review 5.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

6.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

7.  ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.

Authors:  Linan Ha; Takeshi Ichikawa; Miriam Anver; Ross Dickins; Scott Lowe; Norman E Sharpless; Paul Krimpenfort; Ronald A Depinho; Dorothy C Bennett; Elena V Sviderskaya; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

Review 9.  Lessons learned from next-generation sequencing in head and neck cancer.

Authors:  Myriam Loyo; Ryan J Li; Chetan Bettegowda; Curtis R Pickering; Mitchell J Frederick; Jeffrey N Myers; Nishant Agrawal
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

10.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.